Generic equivalents held to same vigorous manufacturing standards as brand-name drugs
THURSDAY, Jan. 17, 2019 (HealthDay News) — The first generic version of Sabril (vigabatrin) has been approved by the U.S. Food and Drug Administration to prevent complex partial seizures in adults and children aged 10 years and older with epilepsy.
“The availability of high-quality generic alternatives of critically important medicines, once the period of patent protection or exclusivity has ended on the brand drug, helps advance access and saves consumers billions of dollars each year,” FDA Commissioner Scott Gottlieb, M.D., said in a statement.
The agency repeated prior assertions that generic equivalents are held to the same vigorous manufacturing standards as brand-name drugs and have been deemed equally safe, effective, and chemically equivalent.
Vigabatrin’s label includes a boxed warning of the possibility of permanent vision loss. The drug’s most common side effects include dizziness, fatigue, insomnia, involuntary eye movement, blurred vision, memory impairment, and weight gain. A more serious adverse reaction may be suicidal thoughts or actions, the FDA said.
Approval of generic vigabatrin tablets was granted to Teva Pharmaceuticals USA, whose parent company is based in Israel.
Copyright © 2019 HealthDay. All rights reserved.
